2023 was an exciting year at ImmunoScape, featuring transformative technical progress, new partnerships, expert additions to our leadership team and more. Read our...
Dec 21, 2023
The collaboration seeks to produce novel off-the-shelf TCR-based bispecific molecules designed to overcome current limitations in cell therapy approaches against solid...
Dec 20, 2023
MiNK Therapeutics combines its unique, proprietary library of T-cell antigens with ImmunoScape’s cutting-edge platform for rapid discovery of novel T-cell...
Dec 19, 2023
Therapeutics for solid tumors remain in a nascent corner of cancer research despite representing 90% of all cancers in adults. Thirty years after the first Chimeric...
Dec 12, 2023
ImmunoScape Appoints Systems Immunology and Computational Biology Expert Dr. John Tsang to its Scientific Advisory Board Expertise from award-winning computational...
Nov 4, 2023
ImmunoScape’s Andreas Wilm offers a behind the scenes look at the machine learning models we trained for research published in Cell Press' Cell Reports – which...
Oct 19, 2023
ImmunoScape Uses Machine Learning to Accurately Predict Antigen Specificity Based on T-Cell Phenotypes in New Peer-Reviewed Research ImmunoScape’s platform accelerates...
Feb 15, 2023
Ayesha Siddiqui from BioSpectrum Asia spoke with our CEO and Co-Founder Choon-Peng (Choon) Ng about the progress around cancer research in Asia for her recent piece....
Jan 20, 2023
Our CEO and co-founder, Choon-Peng (Choon) Ng recently spoke with BioSpectrum Asia about how our unique Deep Immunomics and machine learning platforms can discover and...